APLS Form 144 Filed for 189-Share Sale from Vested Restricted Stock
Rhea-AI Filing Summary
Apellis Pharmaceuticals, Inc. (APLS) Form 144 notice reports a proposed sale of 189 shares of common stock held at Fidelity Brokerage Services with an aggregate market value of $4,572.29. The shares, part of restricted stock that vested on 09/12/2025, were acquired from the issuer as compensation and the filer plans an approximate sale date of 09/15/2025 on NASDAQ. The filing also discloses that the same account sold 548 shares on 09/02/2025 for gross proceeds of $15,386.20. These amounts are small relative to the reported 126,289,910 shares outstanding, and the filer represents no undisclosed material adverse information.
Positive
- Full Rule 144 disclosure provided including acquisition date, nature of acquisition, broker, planned sale date, and prior sales
- Insider attestation present stating no undisclosed material adverse information
Negative
- None.
Insights
TL;DR: Routine insider sale from vested restricted stock; immaterial to overall share base.
The filing indicates a small, scheduled sale of vested restricted common stock: 189 shares valued at $4,572.29, with a recent prior sale of 548 shares for $15,386.20. Given the issuer's stated 126,289,910 shares outstanding, these transactions represent a negligible percentage of the float and are typical of insiders monetizing small vested awards for liquidity. The filing includes the standard attestation about absence of undisclosed material information.
TL;DR: Disclosure aligns with Rule 144 requirements; no governance red flags from this notice alone.
This Form 144 provides required details: acquisition date (09/12/2025), nature (restricted stock vesting), planned sale date (09/15/2025), broker, and historical sales in the past three months. The signatures/attestations included are standard. There is no indication in the document of irregular trading plans or undisclosed material information, and the transaction sizes are immaterial versus total shares outstanding.